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Abstract
Introduction: Antibiotic resistance decreases success of Helicobacter pylori (Hp) eradication. Recently published 
results show low rate of resistance and better compliance with moxifloxacin based regiments.
Aims&methods: Whether 7 days moxifloxacin with lansoprasole and amoxycillin can be compared with 10 days 
moxifloxacin with lansoprasole and amoxycillin according to moxifloxacin resistance. Patients with non-ulcer dyspepsia 
who had culture and histology positive Hp infection (n = 150) were randomly assigned into two groups. The first group 
(n = 75) received moxifloxacin 400 mg/d during 7 days and the other (n = 75) received moxifloxacin 400 mg/d during 
10 days. All patients received amoxycillin 1 g twice daily, lansoprasole 30 mg twice daily. All Hp cultures were tested for 
sensitivity to moxifloxacin.
Results: 138 patients (92%) completed the study, 68 in the first group and 70 in the second. Eradication rates were 84% 
(57/68) and 76% (57/75) in the 7 days moxifloxacin group and 90% and 84% in the second group (63/70, 63/75) 
according to the PP and ITT analysis; p = n.s. Among 129 patients (86% of study group), 6% of strains were primary 
resistant to moxifloxacin.
Eradication of moxifloxacin sensitive/resistant strains was 98%/66%, p < 0.05
Conclusion: According to our results we recommend 7 days moxiflixacin based triple therapy.
Introduction
During the last few decades a large number of surveys
have been conducted to show the importance of Helico-
bacter pylori infection as the main etiologic factor in
chronic active gastritis, peptic ulcers and gastric malig-
nancies [1]. European guidelines for Helicobacter pylori
eradication recommend a triple regimen, combining pro-
ton pump inhibitor (PPI), claritromycin, and either amox-
icillin or metronidazole as the first-line treatment [2,3].
Resistance to antibiotics is a major cause of eradication
failure [4-6]. Currently available first-line anti H. pylori
therapies may fail in up to 30% of patients [7,8] leading to
significant increase of antimicrobial resistance, particu-
larly against key antibiotics, claritromycin and/or met-
ronidazole [9,10]. Resistance to amoxicillin and
tetracycline is generally very low, even absent and is clini-
cally insignificant [11]. To avoid resorting to rescue thera-
pies, recent clinical trials have demonstrated that
fluoroquinolone-based triple regimens may provide
important options for the treatment [12-14]. Moxifloxa-
cin-based triple regimens have been shown as a promis-
ing alternative by proving to have a good efficacy in the
treatment of H. pylori infection [14-16]
Moxifloxacin is a second-generation fluoroquinolone
widely used to treat respiratory and skin infections [17]. It
is rapidly absorbed after oral administration, penetrates
tissues well, and its half-life of 9-16 hours allows a single
daily dose. The drug is well tolerated with only mild gas-
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trointestinal disturbances (nausea and diarrhoea) as the
most common side-effects [18].
According to these findings, in 2007 our group already
investigated and proved the efficacy of one week of moxi-
floxacin-based treatment comparing with the standard
treatment therapy [19].
The aim of this study was to determine the impact of
moxifloxacine resistance and period of treatment on the
effectiveness of a treatment regimen for eradication of H.
pylori infection.
Petients, matherials and methods
The study was conducted at the Department of Hepato-
gastroenterology, Internal Medical Clinic in the Clinical
Hospital "Sveti Duh", Zagreb, Croatia between June 2007
and June 2008.
This was an open, randomized, comparative clinical
trial with parallel groups of patients.
Before entering the study, each patient reviewed and
signed an informed consent form approved by the Local
Ethics Committee. Standards of Good Clinical Practice
and The declaration of Helsinki were followed.
Patients' recruitment
Consecutive patients of either sex and at least 18 years of
age were recruited from those referred to Endoscopy Ser-
vices for diagnostic upper-gastrointestinal endoscopy for
evaluation of dyspeptic symptoms, and found to suffer
from non-ulcer dyspepsia and concomitant H. pylori
infection.
Patients were not suitable for the study if one of the cri-
teria was met: diagnostically duodenal or gastric ulcers,
gastrointestinal bleeding, previous attempts to eradicate
H. pylori and usage of antibiotics and/or anti-gastric acid
therapy within the previous 30 days and/or bismuth ther-
apy within 90 days and usage of non-steroidal anti-
inflammatory drugs, corticosteroids or gold-based drugs.
The presence of severe concurrent diseases (cardio respi-
ratory, renal, hepatic, neurological, pulmonary, meta-
bolic, hematological and endocrine and suspected or
confirmed malignancy), a condition associated with poor
compliance (alcohol and drug abuse) pregnancy and
breastfeeding were also exclusion criteria.
Procedures used to diagnose Helicobacter pylori infection
Endoscopy was performed with an OlympusR FB20
endoscope (Olympus Optical Co., Tokyo, Japan) before
treatment and 4-6 weeks after the treatment. Patients
fasted a night before testing. Eight gastric mucosal biop-
sies per patient were taken with biopsy forceps (Olympus
FB 24-K) in order to perform rapid urease testing (CLO
test), histology and culture.
One sample each from antrum and corpus were used
for the CLO test (Delta West Ltd. Bently Western Austra-
lia) which was considered positive if there was change in
color within 24 hours. Histology was performed on two
biopsies, each from the antrum and corpus, following the
guidelines of the Sydney System. (2004- 12-Price AB
1991)
The biopsies were placed in separate tubes containing
buffered neutral 3.7% formaldehyde solution. Hematoxy-
lineosin stain was used to grade gastritis and Giemsa
stain to detect H. Pylori.
One antral and one corpus gastric biopsy samples were
taken for culture and put in a sterile receptacle containing
before transporting to the microbiology laboratory within
two hours after sterile pulverization specimens were
placed on to fresh Columbia agar with added 7% horse
blood and Iso Vitalex (BBL, Bection-Dickinson, Mary-
land, USA) and incubated for 3-5 days at 35-37°C under
microaerophilic conditions. H. Pylori was identified as
gram negative, spiral or curved rods, producing urease,
catalase and oxidase.
Condition to enroll the patients in to the study was the
following: two of the three tests must be positive. The
treatment was considered successful if all biopsy based
tests did not show the presence of H. Pylori on post-treat-
ment assessment.
If one test suggested persistence of H. pylori a C- urea
test was performed.
The 13C-urea breath test was performed after overnight
fast and collection of baseline exhaled-breath sample. To
delay gastric empting, each patient got a glass of orange
juice (200 ml). Then 75 mg of 13C-urea dissolved in 30 ml
of water was administered orally. 30 minutes later, the
second breath sample was obtained. All breath samples
were analyzed in an isotope-ratio mass spectrometer
(IRMS, Wagner Analysen Technik, Bremen, Germany).
An increase of 13C02 exceeding the baseline value by more
than 4‰ indicated the presence of H. pylori.
Determination of H. pylori resistance
All positive cultures were tested for sensitivity to moxi-
floxacin and amoxicillin using E-test (AB Biodisk, Swe-
den), which determined minimum inhibitory
concentration (MIC). The grown H. pylori colonies were
resuspended in 2 li Dulbecco's modified Eagle's cell cul-
ture medium after three to five days. From this suspen-
sion 100 microliters were flooded on Columbia agar
plates containing 7% horse blood. When the surface had
dried, E-stripes were placed on the agar. All plates were
incubated under microaerophilic conditions at 37°C as
described above. They were red after 48 hours.
The MIC was defined as the lowest concentration
including complete growth inhibition. The cut-off points
for determining a strain as resistant were as follows: 2 μg/
ml for moxifloxacin and 2.25 μml for amoxicillin.Bago et al. Annals of Clinical Microbiology and Antimicrobials 2010, 9:13
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Treatment groups
The patients were distributed randomly to one of the fol-
lowing regimes:
1. LAM 7: lansoprazole 30 mg + amoxicillin 1000 mg +
moxifloxacin 400 mg for 7 days
2. LAM 10: lansoprazole 30 mg + amoxicillin 1000 mg
+ moxifloxacin 400 mg for 10 days
A physical examination was carried out and medical
history was taken during the pre-study visit. All three
drugs were distributed in packs in 14 single doses and
g i v e n  t o  p a t i e n t s  w h o  w e r e  i n s t r u c t e d  t o  t a k e  d r u g s
together two times a day, after breakfast and dinner. Each
patient was asked to monitor and document all symp-
toms during therapy. Therapy compliance was assessed
by pill count at the end of the treatment and defined as
intake of >80% of the distributed medication.
Between 4 and 6 weeks after the treatment the follow
up was performed, during which all changes in clinical
symptoms and signs were documented. At the same time
the second endoscopy was arranged, before which the
investigators were not familiar with the results of E-test.
While assessing the biopsy samples, the microbiologist
and the pathologist were blinded to the treatment
regimes, distributed to patients.
Statistics
A n a l y s i s  o f  e f f i c a c y  o f  H .  p y l o r i  e r a d i c a t i o n  w a s  p e r -
formed on an intention-to-treat (ITT) and per protocol
(PP) basis. The ITT analysis included all enrolled patients
who received at least one dose of included drugs. The PP
analysis included only those patients who complied with
the study protocol (>80% of the assigned medication) and
underwent a second endoscopy between 4 and 6 weeks
after the treatment. All results of the treatment are
expressed as percentages with 95% confidence intervals.
The rates of H. pylori eradication in different groups were
analyzed by Student's t-test. Statistical significance was
taken at p < 0.05. χ2 test was used to compare categorical
variables, while the analysis of variance was used to com-
pare the demographic data.
Results
Clinical and demographic variables, compliance and loss 
from follow up
Between June 2007 and June 2008 a total of 150 patients
enrolled in the study. The groups did not differ in base-
line characteristics, as summered in Table 1.
The mean age was 52 ± 13. According to gender, 48%
were male and 52% were female.
All the patients were included in the ITT analysis. 12
patients (8%) did not complete the study for one of the
following reasons: loss from follow up (n = 1), refusal to
go under a second endoscopy (n = 3), adverse effects
leading to discontinuation of treatment (n = 5), con-
curred disapproved medication (n = 2) and taking less
than 80% of the prescribed medicines (n = 1). Those
patients were excluded from PP analysis.
Helicobacter pylori eradication
According to ITT and PP analysis with their respective
95% confidence intervals, H. pylori eradication rates did
not show a significant difference between LAM 7 and
LAM 10 protocols, as is presented in Table 2.
Primary resistance
MIC determination was successful in samples from 92%
(138/150).
Death of the H. pylori strain, fungal overgrowth or neg-
ative culture prevented MIC determination with the E-
test in samples from 8% (12/150 patients). Among 129
patients (86% of the entire study group), 6% of strains
were primary resistant to moxifloxacin. Eradication of
moxifloxacin sensitive/resistant strains were 98%/66%, p
< 0.005. All 138 strains were sensitive to amoxicillin.
Impact of primary resistance on eradication of H. pylori
Results of our study suggest that the impact of H. pylori
resistence to moxifloxacin on eradication is statisticaly
significant. There was statistic significance between resis-
tant strains and sensitive strains in LAM 7 protocol (p =
0,006), as well as in LAM 10 group (p = 0.0001).
There was no significant difference between sensitive
strains in LAM 7 and sensitive strains in LAM 10 proto-
col.
Table 1: Baseline demographic characteristics of enrolled patients
LAM 7 LAM 10
Included in ITT analysis (n) 75 75
Age (mean ± SD) 50 ± 13 53 ± 13
Male/female (n) 35/40 37/38 p = 0.869
Smokers (n) 25 23 p = 0.8602
ITT intention-to-treat; SD standard deviation; LAM 7 lansoprazole + amoxicillin + moxifloxacin for 7 days; LAM 10: lansoprazole + amoxicillin 
+ moxifloxacin for 10 days.Bago et al. Annals of Clinical Microbiology and Antimicrobials 2010, 9:13
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Longer period of treatment did not provide signifi-
cantly higher eradication rate, concerning both, sensitive
and resistant strains.
Impact of primary resistance on eradication of H. pylori
is shown in Table 3.
Adverse effects and compliance
Most adverse effects were mild to moderate in intensity.
Two patients in the LAM 7 group discontinued the treat-
ment because of diarrhoea. One patient in the LAM 10
group discontinued the treatment because of epigasrtic
discomfort and two because of diarrhoea. In conclusion,
side effects were more frequent with the larger period of
drug usage, although the difference was not significant.
Detailed overview of adverse effects is shown in a Table
4 below.
Discussion
Until now, many different antimicrobial agents have been
investigated, but choosing the appropriate first-line treat-
ment for the H. pylori treatment remains a challenge.
Apart from antibiotic resistance [4-6], another reason
for treatment failure lies in the fact that side-effects, lon-
ger period of treatment and amount of pills administrated
per day have a negative effect on patients' compliance
[20].
For those reasons, it was necessary to develop a new
therapy scheme, which will result in higher eradication
rates and will include fewer types of antibiotics in therapy
with minor dosages and shorter period of treatment
which provides better patients' compliance, fewer side-
effects and lower expenses of treatment.
In the last few years, new treatment schemes based on
fluoroquinolones, such as levofloxacin and moxifloxacin
have been investigated all over the world.
Up to now, only few studies have evaluated a combina-
tion of levofloxacin, amoxicillin and PPI as first- line regi-
men. Gisbert end al. Reported in 2007 that 10-day
levofloxacin- based combination represents an alterna-
tive to clarythromycin [21].
Antos and al. suggested levofloxacin tripple therapy as
an option with metronidazole and clarithromycin resis-
tant H. pylori strains [22].
However, recent studies from France, Belgium and Ger-
many suggest that resistance of H. pylori to quinolones
has already risen up to 17%, most likely due to wide-
spread use of quinolones in other indications [23-25].
According to Italian investigators, primary resistance to
levofloxacin rised up to 30.3% [26], while in Japan it
amounts 15%. Indonesian scientists proved that flouro-
quinolones show lower resistance rates, 6.9% for cipro-
floxacin, norfloxacin and ofloxacin, 2.8% for sparfloxacin
and gatifloxacin, and 1.4% for levofloxacin and moxiflox-
acin [27].
In Southern Taiwan resistance to ciprofloxacin and
levofloxacin in H. pylori collected from 2004 to 2007
increased significantly compared with the level observed
during 1998 to 2003 (2.8% to 11.8%) [28].
Guided by these facts, in 2007, our group assumed and
proved that moxifloxacin based treatment is effective and
safe option comparing to standard triple regimens due to
increased prevalence of claritromycin resistance (10.8%)
[16] and metronidazole resistance (33%) [29]. Therefore,
it was necessary to invent and to verify a new treatment
Table 3: Effect of primary moxifloxacin resistance on eradication rates
Protocol C-s C-r Susceptibility unknown
LAM 7 56/63 1/4 p = 0,006 0/1
LAM 10 61/64 1/4 p = 0,0001 1/2
p p = 0.310 p = 0.414 p = 0.665
L lansoprazole; A amoxicillin; M moxifloxacin; s sensitive; r resistant
Table 2: H. pylori eradication rates for each treatment regimen
Protocol ITT PP
LAM 7 57/75 = 76% 57/68 = 84%
(95%CI = 0.65 - 0.84) (95%CI = 0.73 - 0.91)
LAM 10 63/75 = 84% 63/70 = 90%
(95%CI = 0.74 - 0.91) (95%CI = 0.81 - 0.95)
p 0.3075 0.4099
ITT intention-to-treat; SD standard deviation; LAM 7 lansoprazole + amoxicillin + moxifloxacin for 7 days; LAM 10: lansoprazole + amoxicillin 
+ moxifloxacin for 10 days.Bago et al. Annals of Clinical Microbiology and Antimicrobials 2010, 9:13
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scheme in our area, which will provide acceptable therapy
outcome.
In order to improve the treatment, according to all
these findings, our study group conducted this survey to
determine an impact of moxifloxacine resistance and
therapy duration on the effectiveness of a treatment regi-
men for eradication of H. pylori infection. Therefore, we
compared H. pylori eradication rates, adverse effects and
patients' compliance.
The eradication rates of 10-days treatment were higher
than those of 7-days treatment by both ITT and PP analy-
ses.
Adverse effects and treatment discontinuation due to
adverse effects were more frequent with the larger period
of drug usage, although, the difference was not signifi-
cant.
According to our results we recommend 7 days moxif-
lixacin based triple therapy because we found no statisti-
caly significant eradication rates comparing LAM 7 and
LAM 10 protocols.
Our assumption is that a low prevalence of fluoroqui-
nolone resistance in Croatia may be associated with the
decreased availability and the short time usage of fluoro-
quinolones in our practice.
In addition, it is essential to investigate the local preva-
lence of H. pylori resistance to antibiotics before intro-
ducing moxifloxacin in practice and, in the future, to
detect a possible increase of resistance to moxifloxacin
after certain period of drug usage.
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